v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 27, 2026
Jun. 28, 2025
Cash Flows from Operating Activities:    
Net income $ 33,010 $ 34,031
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 27,111 28,758
Amortization of fair value inventory step-up 0 2,436
Share-based compensation expense 9,311 9,312
Deferred income taxes 668 (3,231)
Other non-cash operating activities 2,227 1,571
Change in operating assets and liabilities:    
Change in accounts receivable 297 3,557
Change in inventories (1,004) 3,296
Change in prepaid income taxes 6,101 3,346
Change in other assets and other liabilities (12,783) (17,785)
Change in accounts payable and accrued expenses (12,615) (47,896)
Net cash provided by operating activities 52,323 17,395
Cash Flows from Investing Activities:    
Capital expenditures (7,906) (3,754)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (5,565) (11,460)
Proceeds from sale of property, plant and equipment 237 297
Other investments (9,000) (18,083)
Net cash used in investing activities (22,234) (33,000)
Cash Flows from Financing Activities:    
Payments on revolving credit facility 50,000 0
Repayment of term loan borrowings (1,563) (1,563)
Proceeds from employee stock purchase plan 3,123 3,476
Proceeds from exercise of stock options 426 462
Cash used to net share settle employee equity awards (3,500) (4,781)
Other financing activities (14) (36)
Net cash used in financing activities (51,528) (2,442)
Effect of exchange rates on cash and cash equivalents (617) 4,182
Net Change in Cash and Cash Equivalents (22,056) (13,865)
Cash and Cash Equivalents at Beginning of Period 245,440 306,763
Cash and Cash Equivalents at End of Period $ 223,384 $ 292,898